Senseonics Announces Pricing of Public Offering of Common Stock

Senseonics (NYSE:SENS) a medical technology company focused on the development and commercialization of Eversense, a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced the pricing of a registered underwritten public offering of its common stock for proceeds of $130.0 million, before deducting estimated offering expenses payable by Senseonics. All of the shares sold in the offering were sold by Senseonics.

As quoted in the press release:

The offering is expected to close on June 28, 2018, subject to customary closing conditions. In addition, Senseonics has granted the underwriter a 30-day option to purchase up to an additional $19.5 million of shares of its common stock.

BTIG, LLC is acting as sole book-running manager for the offering.

A shelf registration statement on Form S-3 relating to the public offering of the shares of common stock described above was declared effective by the Securities and Exchange Commission (SEC) on April 19, 2018. Before you invest, you should read the prospectus in the registration statement and related prospectus supplement that Senseonics will file with the SEC for more complete information about Senseonics and this offering.

Click here to read the full press release.